The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
The first commercial drug from Madrigal Pharmaceuticals (NASDAQ: MDGL) made a big splash in 2024 when the Food and Drug Administration (FDA) approved Madrigal's Rezdiffra as the first drug in the U.S. to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
The pharmaceutical stock is down more than 7% this year, but institutional investors are still high on the company. Baker Brothers Advisors owns 2.14 million shares, while the Janus Henderson Group owns 2.1 million, and RTW Investments owns 1.99 million shares of Madrigal. Institutional investors hold more than 95% of the company's float.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Is there something those investors are seeing that retail investors are missing? Let's find out.